Research programme: non-nucleoside reverse transcriptase inhibitors - Medivir AB

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Medivir AB

Alternative Names: MIV-170; NNRTI research programme - Medivir AB; Non-nucleoside reverse transcriptase inhibitors research programme - Medivir AB

Latest Information Update: 09 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 06 Jul 2007 Bristol-Myers Squibb terminates its licence for MIV 170
  • 13 Sep 2006 MIV 170 has been licensed to Bristol-Myers Squibb worldwide for the treatment of HIV-1 infections in adult patients
  • 28 Dec 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top